SCHEMBL4058739

SCHEMBL4058739

Fc1ccccc1-c1cnc2nc(CSc3ccccc3)[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
RAB9A P51151 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SCD O00767 1/20 0.43
HPGD P15428 3/20 0.42
PPARG P37231 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
TRPA1 O75762 1/20 0.42
PKM P14618 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055054 0.85 NPC1 (0.54) NPC1RAB9ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL4052646 0.82 SCD (0.45) NPC1RAB9ASMN1; SMN2CYP3A4SCD
SCHEMBL13607955 0.81 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL4054497 0.81 NOS3 (0.47) NPC1RAB9ASMN1; SMN2CYP3A4SCD
SCHEMBL4059592 0.80 SMN1; SMN2 (0.48) NPC1RAB9ASMN1; SMN2CYP3A4SCD
SCHEMBL4052395 0.78 RAB9A (0.46) NPC1RAB9ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL4053685 0.78 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL4055037 0.78 TDP1 (0.65) NPC1RAB9ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL4051509 0.76 SCD (0.63) NPC1RAB9ACYP3A4SCDTRPA1
SCHEMBL4055325 0.76 MAPT (0.44) NPC1RAB9ASMN1; SMN2CYP3A4SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885RAB9A 1184/4885SMN1; SMN2 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.